Myriad Genetics (MYGN) Capital Expenditures Growth (3y) (2012 - 2026)
Myriad Genetics (MYGN) Capital Expenditures Growth (3y) (2012 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Thermo Fisher Scientific | 213.88 Bn | 209.81 Bn | 8.34 Bn | 16.58% |
| 2 | Danaher | 140.65 Bn | 136.30 Bn | 3.61 Bn | -6.49% |
| 3 | Idexx Laboratories | 46.02 Bn | 45.83 Bn | 779.09 Mn | -3.55% |
| 4 | Agilent Technologies | 39.85 Bn | 38.05 Bn | 990.00 Mn | 10.06% |
| 5 | Iqvia Holdings | 39.20 Bn | 37.12 Bn | 1.44 Bn | 7.36% |
| 6 | Natera | 38.80 Bn | 37.70 Bn | 696.04 Mn | 139.42% |
| 7 | Illumina | 30.11 Bn | 28.94 Bn | 770.00 Mn | -5.23% |
| 8 | Mettler Toledo International | 28.66 Bn | 28.61 Bn | 650.22 Mn | -1.12% |
| 9 | Quest Diagnostics | 26.24 Bn | 25.61 Bn | 1.03 Bn | 9.89% |
| 10 | Myriad Genetics | 297.97 Mn | 173.57 Mn | 137.60 Mn | -38.75% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -38.75% |
| Dec 31, 2025 | -31.46% |
| Sep 30, 2025 | -13.14% |
| Jun 30, 2025 | -42.53% |
| Mar 31, 2025 | -5.60% |
| Dec 31, 2024 | 1.92% |
| Sep 30, 2024 | -33.50% |
| Jun 30, 2024 | 68.10% |
| Mar 31, 2024 | -26.58% |
| Dec 31, 2023 | -42.79% |
| Sep 30, 2023 | 76.52% |
| Jun 30, 2023 | -85.99% |
| Mar 31, 2023 | 98.60% |
| Dec 31, 2022 | 59.47% |
| Jun 30, 2022 | 43.10% |
| Mar 31, 2022 | 26.67% |
| Dec 31, 2021 | 6.69% |
| Sep 30, 2021 | 109.19% |
| Jun 30, 2021 | -64.41% |
| Mar 31, 2021 | 34.78% |